Navigation Links
MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
Date:5/14/2009

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 2009, the International Conference of the American Thoracic Society, in San Diego on May 18, 2009.

The four posters can be viewed on Monday, May 18 between 8:15 a.m. and 4:00 p.m. Pacific Time. The presentations are titled:

  • "Unit Dose Budesonide (UDB): A New Submicron Dispersion of Nebulizable Budesonide Studied in 360 Children 12 Months to 8 Years Old with Mild to Moderate Persistent Asthma--The CASTLE I Study"
  • "A Novel Budesonide Formulation for Nebulization Significantly Improves the Amount of Drug Emitted over One Minute in a Simulated Pediatric Tidal Breathing Model"
  • "A Novel Aqueous Dispersion of Budesonide Significantly Improves the Aerodynamic Particle Sizing Distribution of Budesonide from Various Jet Nebulizers Compared to a Marketed Budesonide Suspension"
  • "Comparative Pharmacodynamics and Pharmacokinetics of MAP0005 (Formoterol-Budesonide Combination Particles Delivered via the Tempo(R) Inhaler) in Mild to Moderate Asthmatics"

Copies of the posters will be available under the Publications tab of the MAP Pharmaceuticals website on Monday, May 18.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

    Contact:
    MAP Pharmaceuticals, Inc.
    Lisa Borland
    Media Contact
    650-386-3122
    lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
4. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
5. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
6. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology: